Mitochondrial electron transport chain and redox machinery (mETC) (mETC)

The mitochondrial redox machinery, primarily comprising the electron transport chain (ETC) complexes I through IV and ATP synthase, is the central hub for cellular energy production and reactive oxygen species (ROS) generation (PMID: 24037443). Under physiological conditions, these complexes facilitate the transfer of electrons to oxygen, creating a proton gradient used for ATP synthesis, while a small percentage of electrons naturally leak from the chain to form superoxide radicals (PMC4049078). In various pathologies, such as cancer and neurodegeneration, this machinery becomes dysfunctional, leading to excessive ROS production that causes oxidative damage to DNA, proteins, and lipids (PMID: 19143302). Therapeutic strategies targeting this system include the use of mitochondrial-targeted antioxidants like MitoQ to scavenge ROS or specific inhibitors like metformin that modulate complex I activity to alter cellular metabolism (PMID: 10839993). Because mitochondria are essential for the survival of almost all cell types, targeting this machinery requires high specificity to avoid systemic toxicity, such as lactic acidosis or unintended metabolic crisis in healthy tissues (StatPearls: NBK554562).

Other names

Mitochondrial respiratory chainOxidative phosphorylation systemROS generating machineryMitochondrial redox systemMitochondrial electron transport chain

Drugs targeting this machinery typically act by inhibiting specific complexes of the electron transport chain, such as Complex I inhibition by metformin to reduce gluconeogenesis and ROS production (PMID: 10839993). Other agents may act as mitochondrial uncouplers that dissipate the proton gradient or as targeted antioxidants (e.g., MitoQ) that accumulate in the mitochondrial matrix to neutralize superoxide and prevent lipid peroxidation (PMID: 24037443). Some drugs also target the mitochondrial permeability transition pore to regulate apoptosis (PMID: 19143302).